Advanced search
Publication Cover
Clinical Ophthalmology Volume 13, 2019 - Issue
Submit an article Journal homepage
108
Views
3
CrossRef citations to date
0
Altmetric
RAPID COMMUNICATION

Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review

Richard Teofilo Atallah1 Rutgers New Jersey Medical School , Newark, NJ, USA
,
Maria Virginia Castanos2 Department of Research, Eye and Ear Infirmary of Mount Sinai, New York, NY, USA;3 Department of Ophthalmology, New York Eye & Ear Infirmary of Mount Sinai, New York, NY, USA
,
Richard Najac2 Department of Research, Eye and Ear Infirmary of Mount Sinai, New York, NY, USA
&
Eric Donnenfeld4 Ophthalmic Consultants of Long Island, New York University Medical Center, Garden City, NY, USACorrespondence[email protected]
Pages 1033-1037 | Published online: 19 Jun 2019

References

  • Craig JP, Nichols KK, Nichols JJ, et al. TFOS DEWS II Definition and Classification Report. Ocular Surf. 2017;15(3):276–283.
  • Perez VL, Pflugfelder SC, Zhang S, Shojaei A, Haque R. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocular Surf. 2016;14(2):207–215. doi:10.1016/j.jtos.2016.01.001
  • Pflugfelder SC, Stern ME, Zhang S, Shojaei A. LFA-1/ICAM-1 interaction as a therapeutic target in dry eye disease. J Ocul Pharmacol Thera. 2016;33(1):5–12. doi:10.1089/jop.2016.0105
  • Holland EJ, Whitley WO, Sall K, et al. Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials. Curr Med Opin. 2016;32(10):1759–1765. doi:10.1080/03007995.2016.1210107
  • Donnenfeld ED, Karpecki PM, Majmuda PA, et al. Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-Year, multicenter, randomized, placebo-controlled study. Cornea. 2016;35(6):741–748. doi:10.1097/ICO.0000000000000803
  • Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry eye disease: results of a phase III randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology. 2017;124(1):53–60. doi:10.1016/j.ophtha.2016.09.025
  • Lienert JP, Tarko L, Uchino M, Christen WG, Schaumberg DA. Long-term natural history of dry eye disease from the patient’s perspective. Ophthalmology. 2016;123(2):425–433. doi:10.1016/j.ophtha.2015.10.011
  • Jones L, Downie L, Korb D, et al. TFOS DEWS II management and therapy report. Ocular Surf. 2017;15(3):575–628. doi:10.1016/j.jtos.2017.05.006
  • Xiidra Prescribing Information. Shire, July 2016.
  • Tauber J, Holland EJ, Baudouin C et al. Response to lifitegrast 5.0% for the treatment of dry eye disease: responder analysis for reductions in eye dryness score in two phase 3 randomized controlled trials. Presented at ISOPT Clinical March 1-3, 2018; Tel Aviv, Israel.
  • Tauber J, Karpecki P, Latkany R, et al. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study. Ophthalmology. 2015;122(12):2423–2431. doi:10.1016/j.ophtha.2015.08.001

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.